pharmacoeconomics | CMAC

pharmacoeconomics

Analysis of effectiveness criteria in pharmacoeconomic studies of antimicrobial agents proposed for inclusion in the Russian essential drug list in the 2014 -2016

Objective. To estimate proportion of hard and surrogate endpoints used as effectiveness criteria in pharmacoeconomic studies of antimicrobial drugs. Materials and Methods. The pharmacoeconomic studies of 30 antimicrobial agents proposed for inclusion in the Russian essential drug list in the 2014-2016 were reviewed. Results. A total of 47 effectiveness criteria were analyzed, of them 40.4% were hard endpoints. Two studies of antifungal drugs used the hard endpoints only. The hard endpoints were used in 58.

Cefixime vs Ciprofloxacin for Acute Uncomplicated Cystitis: Clinico-Economic Study

Objective. To evaluate clinico-economical effectiveness of short course of cefixime and ciprofloxacin in women with acute uncomplicated cystitis. Materials and Methods. A prospective randomized clinico-economic study of effectiveness of cefixime and ciprofloxacin in 104 patients with acute uncomplicated cystitis. Results. At visit 2 (day 8) microbiological cure rates were detected in 95.9%, 55.6% and 71.4% of patients from Group 1 (cefixime), Group 2-a (ciprofloxacin 250 mg BID) and Group 2-b (ciprofloxacin 500 mg BID), respectively.

Optimizing the Management of Community-Acquired Pneumonia in Hospitalized Patients on the Basis of Modifiable Factors

Choice of empiric therapy should be based on complex of data on etiology and local antimicrobial resistance trends as well as on clinical-economic analysis. According to our results, from the pharmacoeconomic point of view the most optimal agents for …

Clinical and Economical Expediency of Posaconazole Comparing with Fluconazole and Itraconazole in Primary Prophylaxis of Systemic Mycoses in Severe Neutropenic Patients

For the first time in Russian economic conditions and with use of mathematic modeling, clinical-economic study of posaconazole in comparison with fluconazole/itraconazole for primary prophylaxis of invasive mycoses in patients with severe neutropenia …

Pharmacoeconomics of Chronic Pathologic Process

Pharmacoeconomic studies have become an integral part of evidence based medicine at nowadays. However, difficulties in standardization of pharmaeconomical analysis methods and problems with lifelong therapy of chronic pathologic processes …

Carbapenems: Myths and Reality

This paper presents analysis of microbiological, clinical and pharmacoeconomic studies of carbapenems. Use of carbapenems during the last two decades was not associated with emergence of resistance to these agents among clinically significant human …

The Economic Impact of Staphylococcus aureus Infection

Translated and reprinted with permission from «Emerging Infectious Diseases» 1999;5:9-17.

We modeled estimates of the incidence, deaths, and direct medical costs of Staphylococcus aureus infections in hospitalized patients in the New York City …